J
Jun Liu
Researcher at Sun Yat-sen University
Publications - 1474
Citations - 92168
Jun Liu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 100, co-authored 1165 publications receiving 73692 citations. Previous affiliations of Jun Liu include Shanghai Jiao Tong University & Genome Institute of Singapore.
Papers
More filters
Journal ArticleDOI
Response of Photosynthesis in Maize to Drought and Re-Watering
TL;DR: The higher drought tolerance and rapid recovery capability of SD609 were associated with more effective self-regulation of photochemical activities and photosynthesis-related gene expression, which appears to represent a critical adaptive mechanism to withstand and survive the rapidly changing climate.
Journal ArticleDOI
Molecular Mechanisms of Alveolar Epithelial Stem Cell Senescence and Senescence-Associated Differentiation Disorders in Pulmonary Fibrosis
TL;DR: Roles of alveolar epithelial stem cell senescence and senescences-associated differentiation disorders in pulmonary fibrosis are examined, exploring the mechanisms mediating and preventing pulmonary fibrogenic crisis and providing a framework for targeted intervention of the molecular mechanisms.
Journal ArticleDOI
Overcoming the blood-brain barrier: Exosomes as theranostic nanocarriers for precision neuroimaging.
TL;DR: The feasibility of fabricating specific exosome-based diagnostic reagents for the application of personalized/precision radiology in the central nervous system based on important recent fundamental discoveries and technological advances is discussed in this article .
Journal ArticleDOI
Long non-coding RNAs lnc-ANGPTL1-3:3 and lnc-GJA10-12:1 present as regulators of sentinel lymph node metastasis in breast cancer.
TL;DR: The results of the present study suggested that lnc-ANGPTL1-3:3 and lNC-GJA10-12:1 may potentially serve a role in SLN metastasis of breast cancer by regulating the PI3K/Akt and MAPK signaling pathways via targeting the miR-302 family, miR -520a-3p,MiR-34a-5p and mi R-449a.
Journal ArticleDOI
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
TL;DR: In the current study of elderly CML patients, initiation of second-line TKIs frequently occurs at doses lower than the recommended starting doses and, despite this, many patients require dose adjustments.